Japan has given the green light to two trailblazing stem-cell treatments one targeting Parkinson’s disease and another aimed at severe heart failure, according to the manufacturer and local media reports published Friday (March 6). Both therapies could be in patients’ hands within a matter of months.
Pharmaceutical company Sumitomo Pharma announced regulatory approval to produce and sell Amchepry, a Parkinson’s treatment that works by transplanting stem-cell-derived cells directly into the patient’s brain. Simultaneously, Japan’s health ministry approved ReHeart, a regenerative therapy developed by medical startup Cuorips, which deploys sheets of heart muscle cells to encourage new blood vessel growth and restore cardiac function in people suffering from severe heart failure.
The treatments could be accessible to patients as early as this summer, reports suggest. If brought to market, they would represent the world’s first commercially available medical products built on induced pluripotent stem (iPS) cell technology. Japanese researcher Shinya Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012 for his discovery of iPS cells, which have the remarkable ability to develop into virtually any cell type in the human body.
“I hope this will bring relief to patients not only in Japan but around the world,” health minister Kenichiro Ueno told a press conference. “We will promptly carry out all necessary procedures to ensure it reaches all patients without fail.”
In a statement, Sumitomo Pharma said it received “conditional and time-limited approval” to manufacture and market Amchepry under a regulatory framework designed to speed innovative treatments to patients. The Asahi Shimbun newspaper described the authorization as functioning like a provisional license, with safety and effectiveness assessed using fewer patients than a standard drug trial would typically demand.
A clinical study led by Kyoto University researchers indicated the treatment was both safe and capable of improving symptoms in certain patients. The trial enrolled seven Parkinson’s patients between the ages of 50 and 69, each of whom received either five million or ten million cells implanted on both sides of the brain. Researchers derived iPS cells from healthy donors and converted them into precursor cells capable of producing dopamine — the very cells that deteriorate progressively in people living with Parkinson’s. Over a two-year monitoring period, no major adverse effects were recorded, and four of the seven participants demonstrated measurable symptom improvement.
Parkinson’s disease is a progressive neurological disorder that disrupts movement, commonly producing tremors, muscular stiffness, and difficulties with coordination. Roughly 10 million people worldwide are currently living with the condition, according to the Parkinson’s Foundation. Existing treatments largely address symptom management rather than halting or reversing the disease’s progression.
Induced pluripotent stem cells are created by reprogramming mature, specialized cells back into a flexible, youthful state, enabling them to transform into a wide variety of cell types all without the need for embryos. The technology continues to be regarded as one of the most exciting frontiers in contemporary medical science.
